Bioserenity France - Market Entry Research for Intelligent Medical Devices
Company overview
Bioserenity was founded in 2014 and is headquartered at the renowned Institute of Brain and Spine (l’Institut du Cerveau et de la Moelle épinière) in Paris. As one of the most innovative startups in the global field of intelligent and remote healthcare (Disrupt100, 2016), Bioserenity focuses on the R&D and application of wearable intelligent medical devices. Its product portfolio includes intelligent medical devices, smart clothing, companion mobile applications, and AI-driven cloud-based data analysis services. The company's first wearable product, 'Neuronaute,' is specifically designed for long-term monitoring and auxiliary diagnosis of epilepsy. It received CE certification in 2016 and FDA certification in 2017, and has gradually driven a shift in epilepsy diagnosis approaches across Europe. In December 2017, Bioserenity established a branch office in China, marking its official entry into the Asia-Pacific intelligent healthcare market
Research background
With the accelerating trend of intelligent and data-driven transformation in China's healthcare sector, Bioserenity plans to achieve local market deployment for four of its products—including two hardware devices and two service-based solutions—by the end of 2018, primarily targeting the fields of epilepsy and cardiovascular disease monitoring. Prior to market entry, the company urgently requires a comprehensive understanding of key factors such as China's healthcare policy environment, regulatory trends for medical devices and digital health, market demand, and hospital acceptance levels to mitigate market entry risks and refine its market strategy and resource allocation direction
Research scope
In May 2018, CEIDEA Research was commissioned by Bioserenity to conduct a specialized study on its upcoming intelligent medical devices in the Chinese market, integrating both macro-level and micro-level perspectives. The research combines desk-based document review with qualitative in-depth interviews with medical experts. At the macro level, it systematically analyzes policy orientations, industry development trends, and regulatory compliance mechanisms related to intelligent healthcare, remote monitoring, and digital health at both national and regional levels. At the micro level, the study conducts in-depth visits to representative hospitals and medical institutions to explore their level of acceptance, usage pain points, procurement entry barriers, and clinical application scenarios for intelligent monitoring devices. It further investigates actual needs from hospitals regarding both equipment and service components. The research also examines the competitive landscape and potential collaboration models, providing practical insights for product launch and market promotion
Expected outcomes
This research provides Bioserenity with systematic, data-driven, and actionable decision support for its product launch in the Chinese market. It enables a deeper understanding of the local healthcare environment and hospital-specific needs, optimizes product localization strategies and market entry approaches, enhances communication efficiency with key institutions such as hospitals, and ultimately facilitates the efficient introduction and practical application of intelligent monitoring solutions for epilepsy and cardiovascular diseases. This effort will help Bioserenity establish an early market advantage in China's intelligent healthcare sector
Scan to add our research consultant